MediWound (MDWD) Misses Q4 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
March 16, 2023 7:10 AM EDT2022 total revenues of $26.5 million
FDA approval of NexoBrid® in December 2022; U.S. commercial availability expected in the second quarter of 2023
EscharEx® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023
Cash position of $66 million, including cash received for the NexoBrid approval milestone and recent equity financing
Conference call begins today at... More
